

# High-Throughput Screen for Novel Antimicrobials using a Whole Animal Infection Model

Terence I. Moy<sup>†,‡,§</sup>, Annie L. Conery<sup>‡,§</sup>, Jonah Larkins-Ford<sup>‡,§</sup>, Gang Wu<sup>‡,§</sup>, Ralph Mazitschek<sup>¶</sup>, Gabriele Casadei<sup>\_</sup>, Kim Lewis<sup>\_</sup>, Anne E. Carpenter<sup>\_</sup>, and Frederick M. Ausubel<sup>†,‡,§,\*</sup>

Published on June 29, 2009 on <http://pubs.acs.org> | doi: 10.1021/cb900084v

<sup>†</sup>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, <sup>‡</sup>Department of Molecular Biology, <sup>§</sup>Center for Computational and Integrative Biology, and <sup>¶</sup>Center for Systems Biology, Massachusetts General Hospital, Boston, Massachusetts 02114, <sup>\_</sup>Department of Biology, Northeastern University, Boston, Massachusetts 02115, and <sup>\_</sup>Imaging Platform, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142

**ABSTRACT** The nematode *Caenorhabditis elegans* is a unique whole animal model system for identifying small molecules with *in vivo* antiinfective properties. *C. elegans* can be infected with a broad range of human pathogens, including *Enterococcus faecalis*, an important human nosocomial pathogen. Here, we describe an automated, high-throughput screen of 37,200 compounds and natural product extracts for those that enhance survival of *C. elegans* infected with *E. faecalis*. Using a robot to dispense live, infected animals into 384-well plates and automated microscopy and image analysis, we identified 28 compounds and extracts not previously reported to have antimicrobial properties, including six structural classes that cure infected *C. elegans* animals but do not affect the growth of the pathogen *in vitro*, thus acting by a mechanism of action distinct from antibiotics currently in clinical use.